FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Paolo Lissoni

Research Profile

Chemicals & Drugs

Disorders

Procedures

Anatomy

Pineal Gland

Co-author Network

Publications

TOP 3
Luigi Vigoré; Giusy Messina; Fernando Brivio; Luca Fumagalli; Franco Rovelli; Giuseppe DI Fede; Paolo Lissoni
Psychoneuroendocrine modulation of regulatory T lymphocyte system: in vivo and in vitro effects of the pineal immunomodulating hormone melatonin.
Giuseppina Messina; Paolo Lissoni; Paolo Marchiori; Erio Bartolacelli; Fernando Brivio; Luciano Magotti
Enhancement of the efficacy of cancer chemotherapy by the pineal hormone melatonin and its relation with the psychospiritual status of cancer patients.
Fernando Brivio; Luca Fumagalli; Gabriele Fumagalli; Simonetta Pescia; Rinaldo Brivio; Giuseppe Di Fede; Franco Rovelli; Paolo Lissoni
Synchronization of cortisol circadian rhythm by the pineal hormone melatonin in untreatable metastatic solid tumor patients and its possible prognostic significance on tumor progression.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Paolo Lissoni (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: Luigi Vigoré; Giusy Messina; Fernando Brivio; Luca Fumagalli; Franco Rovelli; Giuseppe DI Fede; Paolo Lissoni
Psychoneuroendocrine modulation of regulatory T lymphocyte system: in vivo and in vitro effects of the pineal immunomodulating hormone melatonin.
In vivo (Athens, Greece) 2010;24(5):787-9.
2010: Giuseppina Messina; Paolo Lissoni; Paolo Marchiori; Erio Bartolacelli; Fernando Brivio; Luciano Magotti
Enhancement of the efficacy of cancer chemotherapy by the pineal hormone melatonin and its relation with the psychospiritual status of cancer patients.
Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences 2010;15(4):225-8.
2010: Fernando Brivio; Luca Fumagalli; Gabriele Fumagalli; Simonetta Pescia; Rinaldo Brivio; Giuseppe Di Fede; Franco Rovelli; Paolo Lissoni
Synchronization of cortisol circadian rhythm by the pineal hormone melatonin in untreatable metastatic solid tumor patients and its possible prognostic significance on tumor progression.
In vivo (Athens, Greece) 2010;24(2):239-41.
2010: Giuseppina Messina; Paolo Lissoni; Erio Bartolacelli; Luciano Magotti; Massimo Clerici; Paolo Marchiori; Elisa Colombo
Relationship between psychoncology and psychoneuroendocrinoimmunology (PNEI): enhanced T-regulatory lymphocyte activity in cancer patients with self-punishement, evaluated by Rorschach test.
In vivo (Athens, Greece) 2010;24(1):75-8.
2009: Paolo Lissoni; Giusy Messina; Franco Rovelli; Fernando Brivio; Luca Fumagalli; Sara Villa; Erio Bartolacelli
HER2 expression in breast cancer: correlation with endocrine function and psychological status in operable and metastatic breast cancer.
In vivo (Athens, Greece) 2009;23(6):987-9.
2009: Paolo Lissoni; Fernando Brivio; Luca Fumagalli; Giusy Messina; S Meregalli; G Porro; Franco Rovelli; L Vigorè; E Tisi; G D'Amico
Effects of the conventional antitumor therapies surgery, chemotherapy, radiotherapy and immunotherapy on regulatory T lymphocytes in cancer patients.
Anticancer research 2009;29(5):1847-52.
2008: R Cerrone; Luisa Giani; B Galbiati; Giusy Messina; M Casiraghi; E Proserpio; M Meregalli; P Trabattoni; Paolo Lissoni; Gianstefano Gardani
Efficacy of HT 7 point acupressure stimulation in the treatment of insomnia in cancer patients and in patients suffering from disorders other than cancer.
Minerva medica 2008;99(6):535-7.
2008: Paolo Lissoni; Giusy Messina; D Parolini; A Balestra; Fernando Brivio; Luca Fumagalli; L Vigore; Franco Rovelli
A spiritual approach in the treatment of cancer: relation between faith score and response to chemotherapy in advanced non-small cell lung cancer patients.
In vivo (Athens, Greece) 2008;22(5):577-81.
2008: Paolo Lissoni; Franco Rovelli; Fernando Brivio; Luca Fumagalli; G Brera
A study of immunoendocrine strategies with pineal indoles and interleukin-2 to prevent radiotherapy-induced lymphocytopenia in cancer patients.
In vivo (Athens, Greece) 2008;22(3):397-400.
2008: Paolo Lissoni; Fernando Brivio; Luca Fumagalli; Giusy Messina; Luigi Vigoré; Daniela Parolini; Massimo Colciago; Franco Rovelli
Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors.
Anticancer research 2008;28(2B):1377-81.
2007: Gianstefano Gardani; R Cerrone; C Biella; G Galbiati; E Proserpio; M Casiraghi; J Arnoffi; M Meregalli; P Trabattoni; E Dapretto; Luisa Giani; Giusy Messina; Paolo Lissoni
A progress study of 100 cancer patients treated by acupressure for chemotherapy-induced vomiting after failure with the pharmacological approach.
Minerva medica 2007;98(6):665-8.
2007: Gianstefano Gardani; R Cerrone; C Biella; B Galbiati; E Proserpio; M Casiraghi; O Travisi; M Meregalli; P Trabattoni; L Colombo; Luisa Giani; Giusy Messina; J Arnoffi; Paolo Lissoni
A case-control study of Panicum Miliaceum in the treatment of cancer chemotherapy-induced alopecia.
Minerva medica 2007;98(6):661-4.
2007: Paolo Lissoni; Fernando Brivio; Luca Fumagalli; Giusy Messina; G Secreto; B Romelli; Gabriele Fumagalli; Franco Rovelli; Massimo Colciago; G Brera
Immune and endocrine mechanisms of advanced cancer-related hypercortisolemia.
In vivo (Athens, Greece) 2007;21(4):647-50.
2007: Giusy Messina; Paolo Lissoni; Erio Bartolacelli; Luca Fumagalli; Fernando Brivio; E Colombo; Gianstefano Gardani
Efficacy of IL-2 immunotherapy in metastatic renal cell carcinoma in relation to the psychic profile as evaluated using the Rorschach test.
Anticancer research 2007;27(4C):2985-8.
2006: Gianstefano Gardani; R Cerrone; C Biella; L Mancini; E Proserpio; M Casiraghi; O Travisi; M Meregalli; P Trabattoni; L Colombo; Luisa Giani; MM Vaghi; Paolo Lissoni
Effect of acupressure on nausea and vomiting induced by chemotherapy in cancer patients.
Minerva medica 2006;97(5):391-4.
2006: Paolo Lissoni; Luca Fumagalli; Fernando Brivio; Franco Rovelli; Giusy Messina; G Di Fede; Massimo Colciago; G Brera
Cancer chemotherapy-induced lymphocytosis: a revolutionary discovery in the medical oncology.
Journal of biological regulators and homeostatic agents 2006;20(1-2):29-35.
2006: Fernando Brivio; Luca Fumagalli; Paolo Lissoni; Armando Nardone; Luca Nespoli; Luca Fattori; Marianna Denova; Marco Chiarelli; Angelo Nespoli
Pre-operative immunoprophylaxis with interleukin-2 may improve prognosis in radical surgery for colorectal cancer stage B-C.
Anticancer research 2006;26(1B):599-603.
2006: Paolo Lissoni; P Viganò; A Podraska; R Brivio; Massimo Colciago; M Casu; Vittorio Manganini; C Giuberti; Guido Raffaele Strada; Gianstefano Gardani
Chromogranin A blood concentrations in relation to those of prolactin in hormone-refractory metastatic prostate cancer: possible existence of two independent mechanisms responsible for endocrine resistance.
The International journal of biological markers 2006;21(1):58-9.
2005: Paolo Lissoni; Fernando Brivio; Luca Fumagalli; G Di Fede; G Brera
Enhancement of the efficacy of chemotherapy with oxaliplatin plus 5-fluorouracil by pretreatment with IL-2 subcutaneous immunotherapy in metastatic colorectal cancer patients with lymphocytopenia prior to therapy.
In vivo (Athens, Greece) 2005;19(6):1077-80.
2005: Paolo Lissoni; P Vigano; MM Vaghi; Luciano Frontini; C Giuberti; Vittorio Manganini; M Casu; Fernando Brivio; R Niespolo; Guido Raffaele Strada
A phase II study of tamoxifen in hormone-resistant metastatic prostate cancer: possible relation with prolactin secretion.
Anticancer research 2005;25(5):3597-9.
2005: Paolo Lissoni; S Meregalli; E Bonetto; M Mancuso; Fernando Brivio; Massimo Colciago; Gianstefano Gardani
Radiotherapy-induced lymphocytopenia: changes in total lymphocyte count and in lymphocyte subpopulations under pelvic irradiation in gynecologic neoplasms.
Journal of biological regulators and homeostatic agents 2005;19(3-4):153-8.
2005: Paolo Lissoni; Giusy Messina; Fernando Brivio; Franco Rovelli; G Di Fede; E Mainini; E Veronese
Cortisol response to an acute injection of IL-2 in healthy subjects and cancer patients: a first immunoneuroendocrine standardized clinical test to explore the interactions between immune and neuroendocrine systems.
Journal of biological regulators and homeostatic agents 2005;19(3-4):141-4.
2005: Paolo Lissoni; Alessandra Bignami; Luciano Frontini; Vittorio Manganini; E Dapretto; Gianstefano Gardani; P Viganò; Guido Raffaele Strada
Possible involvement of prolactin in endocrine-resistant metastatic prostate cancer.
The International journal of biological markers 2005;20(2):123-5.
2005: Alessandra Bignami; Paolo Lissoni; Fernando Brivio; F Galbiati; S Pescia; Giusy Messina; Luciano Frontini; S Meregalli; Gianstefano Gardani
The favorable prognostic significance of surgery-induced hyperprolactinemia in node-positive breast cancer patients: ten-year disease-free survival results.
The International journal of biological markers 2005;20(1):60-4.
2004: Luciano Frontini; Paolo Lissoni; MM Vaghi; Maristella Perego; S Pescia; Antonio Ardizzoia; Gianstefano Gardani
Enhancement of the efficacy of weekly low-dose taxotere by the long acting anti-prolactinemic drug cabergoline in pretreated metastatic breast cancer.
Anticancer research 2004;24(6):4223-6.
2004: Paolo Lissoni; Maristella Perego; Elisabetta Veronese; Gabriele Fumagalli; Fernando Brivio; Massimo Colciago; Giusy Messina; Franco Rovelli; Rinaldo Brivio; Gianstefano Gardani
Endocrine effects of erythropoietin in cancer patients.
Hematology (Amsterdam, Netherlands) 2004;9(5-6):363-7.
2004: Paolo Lissoni; MM Vaghi; S Pescia; Franco Rovelli; A Ardizzola; F Valtulina; Fabio Malugani; Gianstefano Gardani; Gabriele Tancini
Biological response modifiers of cancer-related neuroendocrine disorders: efficacy of the long-term dopaminergic agonist cabergoline in the treatment of breast cancer-induced hyperprolactinemia.
Journal of biological regulators and homeostatic agents 2004;18(3-4):291-4.
2004: Paolo Lissoni; Fernando Brivio; Luca Fumagalli; Giusy Messina; V Ghezzi; Luciano Frontini; Luisa Giani; MM Vaghi; Antonio Ardizzoia; Gianstefano Gardani
Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors.
The International journal of biological markers 2004;19(2):135-40.
2003: Paolo Lissoni; Giusy Messina; MM Vaghi; Erio Bartolacelli; L L Massarenti; P Trabattoni; P Meregalli; M Meregalli; C Gavazzeni; Franco Rovelli; Gabriele Tancini; Gianstefano Gardani
A psychoneuroendocrine study of brain dopaminergic sensitivity in locally limited or metastatic cancer patients.
In vivo (Athens, Greece) 2003;17(6):647-50.
2003: Giusy Messina; Paolo Lissoni; Erio Bartolacelli; Gabriele Tancini; Sara Villa; Gianstefano Gardani; Fernando Brivio
A psychoncological study of lymphocyte subpopulations in relation to pleasure-related neurobiochemistry and sexual and spiritual profile to Rorschach's test in early or advanced cancer patients.
Journal of biological regulators and homeostatic agents 2003;17(4):322-6.
2003: Paolo Lissoni; M Chilelli; Sara Villa; L Cerizza; Gabriele Tancini
Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial.
Journal of pineal research 2003;35(1):12-5.
2003: Paolo Lissoni; Fabio Malugani; Fernando Brivio; Alessandra Piazza; Carmen Vintimilla; Luisa Giani; Gabriele Tancini
Total pineal endocrine substitution therapy (TPEST) as a new neuroendocrine palliative treatment of untreatable metastatic solid tumor patients: a phase II study.
Neuro endocrinology letters 2003;24(3-4):259-62.
2003: G Cerea; MM Vaghi; Antonio Ardizzoia; Sara Villa; R Bucovec; Susan Mengo; Gianstefano Gardani; Gabriele Tancini; Paolo Lissoni
Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations.
Anticancer research 2003;23(2C):1951-4.
2003: Paolo Lissoni; Fabio Malugani; Roberta Bukovec; Veronica Bordin; Maristella Perego; Susan Mengo; Antonio Ardizzoia; Gabriele Tancini
Reduction of cisplatin-induced anemia by the pineal indole 5-methoxytryptamine in metastatic lung cancer patients.
Neuro endocrinology letters 2003;24(1-2):83-5.
2003: Paolo Lissoni; Fabio Malugani; Vittorio Manganini; Antonio Ardizzoia; Gianstefano Gardani; Erio Bartolacelli; Giusy Messina; Gabriele Tancini
Psychooncology and cancer progression-related alterations of pleasure-associated neurochemical system: Abnormal neuroendocrine response to apomorphine in advanced cancer patients.
Neuro endocrinology letters 2003;24(1-2):50-3.
2003: Paolo Lissoni; MM Vaghi; Sara Villa; A Bodraska; L Cerizza; Gabriele Tancini; Gianstefano Gardani
Antiprolactinemic approach in the treatment of metastatic breast cancer: a phase II study of polyneuroendocrine therapy with LHRH-analogue, tamoxifen and the long-acting antiprolactinemic drug cabergoline.
Anticancer research 2003;23(1B):733-6.
2003: Paolo Lissoni; Susan Mengo; R Bucovec; Fernando Brivio; Luca Fumagalli; Gabriele Tancini; Gianstefano Gardani
Clinical and biological effects of interleukin-2 with or without a concomitant administration of granulocyte-macrophage colony-stimulating factor in metastatic cancer patients.
In vivo (Athens, Greece) 2003;17(1):73-5.
2002: Paolo Lissoni; Fabio Malugani; Ola Malysheva; Vladimir Kozlov; Moshe Laudon; Ario Conti; Georges Maestroni
Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.
Neuro endocrinology letters 2002;23(4):341-4.
2002: Paolo Lissoni; Fabio Malugani; Veronica Bordin; Ario Conti; Georges Maestroni; Gabriele Tancini
A new neuroimmunotherapeutic strategy of subcutaneous low-dose interleukin-2 plus the long-acting opioid antagonist naltrexone in metastatic cancer patients progressing on interleukin-2 alone.
Neuro endocrinology letters 2002;23(3):255-8.
2002: Paolo Lissoni; R Bucovec; Fabio Malugani; Antonio Ardizzoia; Sara Villa; Gianstefano Gardani; MM Vaghi; Gabriele Tancini
A clinical study of taxotere versus taxotere plus the antiprolactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracyclines.
Anticancer research 2002;22(2B):1131-4.
2002: Paolo Lissoni; Veronica Bordin; MM Vaghi; Luca Fumagalli; A Bordoni; Susan Mengo; R Bucovec; Elena Fumagalli; Fabio Malugani; Antonio Ardizzoia; Luisa Giani; Gianstefano Gardani; Gabriele Tancini
Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.
Anticancer research 2002;22(2B):1061-4.
2002: Paolo Lissoni; MM Vaghi; Antonio Ardizzoia; Fabio Malugani; Elena Fumagalli; Veronica Bordin; Luca Fumagalli; A Bordoni; Susan Mengo; Gianstefano Gardani; Gabriele Tancini
A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
In vivo (Athens, Greece) 2002;16(2):93-6.
2002: Fernando Brivio; Paolo Lissoni; Franco Rovelli; Angelo Nespoli; Franco Uggeri; Luca Fumagalli; Gianstefano Gardani
Effects of IL-2 preoperative immunotherapy on surgery-induced changes in angiogenic regulation and its prevention of VEGF increase and IL-12 decline.
Hepato-gastroenterology 2002;49(44):385-7.
2002: Paolo Lissoni
Is there a role for melatonin in supportive care?
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2002;10(2):110-6.
2002: Paolo Lissoni; Fabio Malugani; Marilena Casu; Roberta Bukovec; Remo Egardi; Veronica Bordin; Elena Fumagalli; Susan Mengo; Gianstefano Gardani
Effect of bicalutamide therapy on prolactin response to L-dopa in metastatic prostate cancer patients.
Neuro endocrinology letters 2002;23(1):61-3.
2001: Fernando Brivio; Paolo Lissoni; Maristella Perego; A Lissoni; Luca Fumagalli
Abrogation of surgery-induced IL-6 hypersecretion by presurgical immunotherapy with IL-2 and its importance in the prevention of postoperative complications.
Journal of biological regulators and homeostatic agents 2001;15(4):370-4.
2001: Paolo Lissoni; P Cangemi; D Pirato; maria grazia roselli; Franco Rovelli; Fernando Brivio; Fabio Malugani; Georges Maestroni; Ario Conti; Moshe Laudon; O Malysheva; Luisa Giani
A review on cancer--psychospiritual status interactions.
Neuro endocrinology letters 2001;22(3):175-80.
2001: Paolo Lissoni; Elena Fumagalli; Fabio Malugani; Antonio Ardizzoia; R Bucovec; Gabriele Tancini; Gianstefano Gardani
Stimulation of IL-12 secretion by GM-CSF in advanced cancer patients.
Journal of biological regulators and homeostatic agents 2001;15(2):163-5.
2001: Paolo Lissoni; Fabio Malugani; A Bonfanti; R Bucovec; S Secondino; Fernando Brivio; A Ferrari-Bravo; R Ferrante; L Vigoré; Franco Rovelli; Mario Mandalà; Simonetta Viviani; Luca Fumagalli; Gianstefano Gardani
Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1.
Journal of biological regulators and homeostatic agents 2001;15(2):140-4.
2001: Paolo Lissoni; Franco Rovelli; D Vellani; Fabio Malugani; R Bucovec; L Chapovalenko; Elena Fumagalli; Gianstefano Gardani
Stimulation of IL-18 secretion by IL-2 in patients with advanced cancer.
The International journal of biological markers 2001;16(2):146-7.
2001: D Viganò; Paolo Lissoni; Franco Rovelli; maria grazia roselli; Fabio Malugani; C Gavazzeni; Ario Conti; Georges Maestroni
A study of light/dark rhythm of melatonin in relation to cortisol and prolactin secretion in schizophrenia.
Neuro endocrinology letters 2001;22(2):137-41.
2001: Paolo Lissoni; R Bucovec; A Bonfanti; Luisa Giani; A Mandelli; maria grazia roselli; Franco Rovelli; Luca Fumagalli
Thrombopoietic properties of 5-methoxytryptamine plus melatonin versus melatonin alone in the treatment of cancer-related thrombocytopenia.
Journal of pineal research 2001;30(2):123-6.
2001: Paolo Lissoni; Franco Rovelli; Fabio Malugani; R Bucovec; Ario Conti; Georges Maestroni
Anti-angiogenic activity of melatonin in advanced cancer patients.
Neuro endocrinology letters 2001;22(1):45-7.
2001: Paolo Lissoni; MM Vaghi; Antonio Ardizzoia; Elena Fumagalli; Gabriele Tancini; Gianstefano Gardani; Ario Conti; Georges Maestroni
Efficacy of monochemotherapy with docetaxel (taxotere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer.
Neuro endocrinology letters 2001;22(1):27-9.
2001: Paolo Lissoni; Franco Rovelli; N Baiocco; G Tangini; Luca Fumagalli
A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone.
Anticancer research 2001;21(1B):777-9.
2000: Paolo Lissoni; Fernando Brivio; Franco Rovelli; Gabriele Fumagalli; Fabio Malugani; MM Vaghi; S Secondino; R Bucovec; Gianstefano Gardani
Serum concentrations of interleukin-18 in early and advanced cancer patients: enhanced secretion in metastatic disease.
Journal of biological regulators and homeostatic agents 2000;14(4):275-7.
2000: Paolo Lissoni; E Fugamalli; Fabio Malugani; Antonio Ardizzoia; S Secondino; Gabriele Tancini; Gianstefano Gardani
Chemotherapy and angiogenesis in advanced cancer: vascular endothelial growth factor (VEGF) decline as predictor of disease control during taxol therapy in metastatic breast cancer.
The International journal of biological markers 2000;15(4):308-11.
2000: Fernando Brivio; R Gilardi; R Bucocev; R Ferrante; R Rescaldani; L Vigoré; Luca Fumagalli; Angelo Nespoli; Paolo Lissoni
Surgery-induced decline in circulating dendritic cells in operable cancer patients: a possible explanation of postoperative immunosuppression.
Hepato-gastroenterology 2000;47(35):1337-9.
2000: Fernando Brivio; Paolo Lissoni; R Gilardi; R Ferrante; L Vigore; L Curzi; Franco Uggeri; Angelo Nespoli; Luca Fumagalli
Abrogation of surgery-induced decline in circulating dendritic cells by subcutaneous preoperative administration of IL-2 in operable cancer patients.
Journal of biological regulators and homeostatic agents 2000;14(3):200-3.
2000: Paolo Lissoni; Mario Mandalà; Fernando Brivio
Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin.
European urology 2000;38(1):115-8.
2000: Paolo Lissoni; S Bolis; Fernando Brivio; Luca Fumagalli
A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
Anticancer research 2000;20(3B):2103-5.
2000: Paolo Lissoni; Mario Mandalà; Franco Rovelli; M Casu; Francesco Rocco; Gabriele Tancini; Epifanio Scardino
Paradoxical stimulation of prolactin secretion by L-dopa in metastatic prostate cancer and its possible role in prostate-cancer-related hyperprolactinemia.
European urology 2000;37(5):569-72.
2000: A Bonfanti; Paolo Lissoni; R Bucovec; Franco Rovelli; Fernando Brivio; Luca Fumagalli
Changes in circulating dendritic cells and IL-12 in relation to the angiogenic factor VEGF during IL-2 immunotherapy of metastatic renal cell cancer.
The International journal of biological markers 2000;15(2):161-4.
2000: Paolo Lissoni
Modulation of anticancer cytokines IL-2 and IL-12 by melatonin and the other pineal indoles 5-methoxytryptamine and 5-methoxytryptophol in the treatment of human neoplasms.
Annals of the New York Academy of Sciences 2000;917():560-7.
2000: Veronica Bordin; Luisa Giani; S Meregalli; Roberta Bukovec; MM Vaghi; Mario Mandalà; F Paolorossi; Antonio Ardizzoia; Gabriele Tancini; S Barni; F Frigerio; Luca Fumagalli; A Bordoni; G Valsuani; G Di Felice; Paolo Lissoni
Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients.
Urologia internationalis 2000;64(1):3-8.
2000: A Ferrari-Bravo; Claudio Franciosi; Paolo Lissoni; Luca Fumagalli; F Uggeri
Effects of oncological surgery on endothelin-1 secretion in patients with operable gastric cancer.
The International journal of biological markers 2000;15(1):56-7.
2000: Paolo Lissoni; Fernando Brivio; R Ferrante; L Vigore; MM Vaghi; Elena Fumagalli; R Bucovec; Fabio Malugani; Luca Fumagalli
Circulating immature and mature dendritic cells in relation to lymphocyte subsets in patients with gastrointestinal tract cancer.
The International journal of biological markers 2000;15(1):22-5.
1999: Mario Mandalà; Paolo Lissoni; Antonio Ardizzoia; S Barni; Franco Rovelli; G Confalonieri; Fabio Malugani; C Moro; Gabriele Fumagalli; Luisa Giani; Gabriele Tancini
Endocrinological study of the dopaminergic regulation of prolactin release in metastatic breast cancer.
Tumori 1999;85(6):494-7.
1999: Paolo Lissoni; S Barni; Mario Mandalà; Antonio Ardizzoia; F Paolorossi; MM Vaghi; R Longarini; Fabio Malugani; Gabriele Tancini
Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status.
European journal of cancer (Oxford, England : 1990) 1999;35(12):1688-92.
1999: Fernando Brivio; Paolo Lissoni; Luca Fumagalli; M Girlando; M T Marsili; Angelo Nespoli; Franco Uggeri
Pre-operative IL-2 immunoprophylaxis of cancer recurrence: long-term clinical results of a phase II study in radically operable colorectal cancer.
Oncology reports 1999;6(6):1205-7.
1999: Paolo Lissoni; L Vigore; R Ferranti; Roberta Bukovec; S Meregalli; mario mandala; S Barni; Gabriele Tancini; Luca Fumagalli; Luisa Giani
Circulating dendritic cells in early and advanced cancer patients: diminished percent in the metastatic disease.
Journal of biological regulators and homeostatic agents 1999;13(4):216-9.
1999: Paolo Lissoni; R Bucovec; S Meregalli; Luca Fumagalli; L Vigorè; R Ferrante; Fernando Brivio
IL-2 immunotherapy-induced increase in IL-12 blood concentrations may depend on an increase in circulating dendritic cell number.
The International journal of biological markers 1999;14(3):195-7.
1999: Paolo Lissoni; S Bolis; Mario Mandalà; Simonetta Viviani; E Pogliani; S Barni
Blood concentrations of tumor necrosis factor-alpha in malignant lymphomas and their decrease as a predictor of disease control in response to low-dose subcutaneous immunotherapy with interleukin-2.
The International journal of biological markers 1999;14(3):167-71.
1999: Luca Fumagalli; Paolo Lissoni; G Di Felice; S Meregalli; G Valsuani; Susan Mengo; Franco Rovelli
Pretreatment serum markers and lymphocyte response to interleukin-2 therapy.
British journal of cancer 1999;80(3-4):407-11.
1999: Paolo Lissoni; Fernando Brivio; Simonetta Viviani; Luca Fumagalli
Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy?
Journal of biological regulators and homeostatic agents 1999;13(2):110-4.
1999: Paolo Lissoni; Luca Fumagalli; F Paolorossi; Mario Mandalà
Changes in lymphocyte number during cancer chemotherapy and their relation to clinical response.
The International journal of biological markers 1999;14(2):115-7.
1999: Paolo Lissoni; Gabriele Tancini; F Paolorossi; Mario Mandalà; Antonio Ardizzoia; Fabio Malugani; Luisa Giani; S Barni
Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study.
Journal of pineal research 1999;26(3):169-73.
1999: Paolo Lissoni; Franco Rovelli; S Pittalis; M Casati; Luisa Giani; S Barni; Luca Fumagalli; Moshe Laudon
[Therapy with melatonin does not suppress its endogenous production in healthy volunteers].
Recenti progressi in medicina 1999;90(2):84-5.
1998: Paolo Lissoni; Franco Rovelli; Mario Mandalà; S Barni
Blood concentrations of interleukin-15 in cancer patients and their variations during interleukin-2 immunotherapy: preliminary considerations.
The International journal of biological markers 1998;13(3):169-71.
1998: Paolo Lissoni; Franco Rovelli; Luisa Giani; mario mandala; S Meregalli; S Barni; G Confalonieri; A Bonfanti
Dehydroepiandrosterone sulfate (DHEAS) secretion in early and advanced solid neoplasms: selective deficiency in metastatic disease.
The International journal of biological markers 1998;13(3):154-7.
1998: Paolo Lissoni; Franco Rovelli; Gabriele Fumagalli; G Confalonieri; Fernando Brivio; M Mariani
[Pharmacokinetics of melatonin].
Recenti progressi in medicina 1998;89(7-8):381-2.
1998: Paolo Lissoni; Luca Fumagalli; Franco Rovelli; Fernando Brivio; G Di Felice; F Majorca
In vivo stimulation of IL-12 secretion by subcutaneous low-dose IL-2 in metastatic cancer patients.
British journal of cancer 1998;77(11):1957-60.
1998: Paolo Lissoni; Luca Fumagalli; Luisa Giani; Franco Rovelli; G Confalonieri; S Pescia
Vascular endothelial growth factor (VEGF) serum levels during cancer immunotherapy with IL-2: preliminary considerations.
The International journal of biological markers 1998;13(2):98-101.
1998: Paolo Lissoni; Franco Rovelli; Luisa Giani; C Gavazzeni; M Grazia Roselli; E Mainini; C Mazzi
Endocrine effects of two pineal hormones other than melatonin in healthy volunteers: 5-methoxytryptophol and 5-methoxytryptamine.
Recenti progressi in medicina 1998;89(4):183-5.
1998: Paolo Lissoni; Franco Rovelli; Luisa Giani; Luca Fumagalli; Mario Mandalà
Immunomodulatory effects of IL-12 in relation to the pineal endocrine function in metastatic cancer patients.
Natural immunity 1998;16(5-6):178-84.
1998: Paolo Lissoni; Luisa Giani; S Zerbini; P Trabattoni; Franco Rovelli
Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms.
Natural immunity 1998;16(1):27-33.
1998: Paolo Lissoni; Franco Rovelli; Fernando Brivio; O Brivio; Luca Fumagalli
Circadian secretions of IL-2, IL-12, IL-6 and IL-10 in relation to the light/dark rhythm of the pineal hormone melatonin in healthy humans.
Natural immunity 1998;16(1):1-5.
1998: Paolo Lissoni; Susan Mengo; Mario Mandalà; E Mauri; Fernando Brivio; Franco Rovelli; G Confalonieri; R Longarini; A Bonfante; D Folli; S Meregalli; S Barni; Gabriele Tancini; Luisa Giani
Physiopathology of IL-12 in human solid neoplasms: blood levels of IL-12 in early or advanced cancer patients, and their variations with surgery and immunotherapy.
Journal of biological regulators and homeostatic agents 1998;12(1-2):38-41.
1998: S Barni; Paolo Lissoni; S Meregalli; Antonio Ardizzoia; Susan Mengo; Flavia Musco; D Merlini; Gabriele Tancini
Clinical efficacy of the aromatase inhibitor anastrozole in relation to prolactin secretion in heavily pretreated metastatic breast cancer.
Tumori 1998;84(1):45-7.
1997: Paolo Lissoni
Effects of low-dose recombinant interleukin-2 in human malignancies.
The cancer journal from Scientific American 1997;3 Suppl 1():S115-20.
1997: Paolo Lissoni; Franco Rovelli; S Meregalli; Luca Fumagalli; Flavia Musco; Fernando Brivio; O Brivio; G Esposti
Melatonin as a new possible anti-inflammatory agent.
Journal of biological regulators and homeostatic agents 1997;11(4):157-9.
1997: Paolo Lissoni; Franco Rovelli; M R Rivolta; C Frigerio; Mario Mandalà; S Barni; Antonio Ardizzoia; Fabio Malugani; Gabriele Tancini
Acute endocrine effects of interleukin-12 in cancer patients.
Journal of biological regulators and homeostatic agents 1997;11(4):154-6.
1997: Paolo Lissoni; Franco Rovelli; S Pittalis; M Casati; Maristella Perego; M G Grassi; Fernando Brivio; Luca Fumagalli
Interleukin-12 in early or advanced cancer patients.
European journal of cancer (Oxford, England : 1990) 1997;33(10):1703-5.
1997: S Pittalis; Paolo Lissoni; Luisa Giani; M Casati; N Kropacek; S Orfanò; F Giavolucci; D Merlini
Effect of a chronic therapy with the pineal hormone melatonin on cholesterol levels in idiopathic hypercholesterolemic patients.
Recenti progressi in medicina 1997;88(9):401-2.
1997: Paolo Lissoni; F Paolorossi; Antonio Ardizzoia; S Barni; M Chilelli; M Mancuso; Gabriele Tancini; Ario Conti; Georges Maestroni
A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state.
Journal of pineal research 1997;23(1):15-9.
1997: Paolo Lissoni; Luca Fumagalli; F Paolorossi; Franco Rovelli; maria grazia roselli; Georges Maestroni
Anticancer neuroimmunomodulation by pineal hormones other than melatonin: preliminary phase II study of the pineal indole 5-methoxytryptophol in association with low-dose IL-2 and melatonin.
Journal of biological regulators and homeostatic agents 1997;11(3):119-22.
1997: Paolo Lissoni; S Barni; G Di Felice; F Majorca; Luca Fumagalli
Neopterin, soluble IL-2 receptor and IL-6 secretion during IL-2 cancer immunotherapy: prognostic significance in relation to IL-12 variations.
The International journal of biological markers 1997;12(3):134-6.
1997: Paolo Lissoni; Franco Rovelli; L Fumagalli; E Mauri; S Barni; Gabriele Tancini
Increased blood concentrations of interleukin-12 are associated with a longer survival in untreatable metastatic solid tumor patients: preliminary observations.
The International journal of biological markers 1997;12(3):125-7.
1997: Paolo Lissoni; S Barni; Antonio Ardizzoia; F Paolorossi; Gabriele Tancini; M Andres; Paolo Favini; Epifanio Scardino; Francesco Rocco
[Immunotherapy for metastatic renal carcinoma with interleukin-2 in a subcutanous administration schedule of short duration. Subcutaneous IL-2 in renal carcinoma].
Archivio italiano di urologia, andrologia : organo ufficiale [di] Società italiana di ecografia urologica e nefrologica / Associazione ricerche in urologia 1997;69(3):159-62.
1997: Paolo Lissoni; D Merlini; D Pirato; S Meregalli
Interleukin-4 blood concentrations in early and metastatic human solid neoplasms.
The International journal of biological markers 1997;12(2):75-8.
1997: Paolo Lissoni; Gabriele Tancini; S Barni; F Paolorossi; Antonio Ardizzoia; Ario Conti; Georges Maestroni
Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1997;5(2):126-9.
1997: Epifanio Scardino; Paolo Lissoni; M Andres; Bruno Frea; Paolo Favini; Ervin Kocjancic; Fabrizio Verweij; S Barani; Gabriele Tancini; Francesco Rocco
[Preoperative subcutaneous immunotherapy with interleukin-2 in renal carcinoma with synchronous metastasis: randomized clinico-biological study. Preoperative use of Il-2 in renal carcinoma].
Archivio italiano di urologia, andrologia : organo ufficiale [di] Società italiana di ecografia urologica e nefrologica / Associazione ricerche in urologia 1997;69(1):49-54.
1997: Paolo Lissoni; S Barni; Gabriele Tancini; M Cazzaniga; F Frigerio; M Chilelli; Epifanio Scardino; M Andres; Paolo Favini; T Meroni; F Verwei; A Baccalin; Maurizio Sala; Bruno Frea; Ervin Kocjancic; Francesco Rocco
[Clinical response and survival in metastatic renal carcinoma during subcutaneous administration of interleukin-2 alone. Subcutaneous Il-2 in renal carcinoma].
Archivio italiano di urologia, andrologia : organo ufficiale [di] Società italiana di ecografia urologica e nefrologica / Associazione ricerche in urologia 1997;69(1):41-7.
1997: Paolo Lissoni; M Cazzaniga; S Barni; Maristella Perego; Fernando Brivio; Luca Fumagalli; Gabriele Tancini
Acute effects of pamidronate administration on serum levels of interleukin-6 in advanced solid tumour patients with bone metastases and their possible implications in the immunotherapy of cancer with interleukin-2.
European journal of cancer (Oxford, England : 1990) 1997;33(2):304-6.
1997: Paolo Lissoni; M Cazzaniga; Gabriele Tancini; Epifanio Scardino; R Musci; S Barni; M Maffezzini; T Meroni; Francesco Rocco; Ario Conti; Georges Maestroni
Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone.
European urology 1997;31(2):178-81.
1996: Paolo Lissoni; G Tancini; S Barni; F Paolorossi; F Rossini; P Maffé; L Di Bella
The pineal hormone melatonin in hematology and its potential efficacy in the treatment of thrombocytopenia.
Recenti progressi in medicina 1996;87(12):582-5.
1996: Paolo Lissoni; O Brivio; Fernando Brivio; S Barni; Gabriele Tancini; D Crippa; S Meregalli
Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma.
Journal of pineal research 1996;21(4):239-42.
1996: Paolo Lissoni; F Paolorossi; Gabriele Tancini; Antonio Ardizzoia; S Barni; Fernando Brivio; G J Maestroni; M Chilelli
A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients.
British journal of cancer 1996;74(9):1466-8.
1996: G Di Felice; Luca Fumagalli; F Majorca; S Barni; Antonio Ardizzoia; Gabriele Tancini; Paolo Lissoni
Reactivation of a normal endogenous secretion of interleukin-2 in metastatic cancer patients by a chronic subcutaneous injection of interleukin-2.
Journal of biological regulators and homeostatic agents 1996;10(4):98-9.
1996: Paolo Lissoni; Franco Rovelli; Luisa Giani; Luca Fumagalli; S Meregalli; G Comi; D Merlini
Correlation between IL-12 and IL-2 blood levels in the metastatic neoplastic disease: a possible inhibitory feedback system regulating their secretion.
Journal of biological regulators and homeostatic agents 1996;10(4):92-4.
1996: Paolo Lissoni; F Paolorossi; Gabriele Tancini; S Barni; Antonio Ardizzoia; Fernando Brivio; Barbara Zubelewicz; V Chatikhine
Is there a role for melatonin in the treatment of neoplastic cachexia?
European journal of cancer (Oxford, England : 1990) 1996;32A(8):1340-3.
1996: Paolo Lissoni; S Pittalis; Antonio Ardizzoia; Fernando Brivio; S Barni; Gabriele Tancini; F Pelizzoni; G J Maestroni; Barbara Zubelewicz; Ryszard Braczkowski
Prevention of cytokine-induced hypotension in cancer patients by the pineal hormone melatonin.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1996;4(4):313-6.
1996: Fernando Brivio; Paolo Lissoni; G Alderi; S Barni; F Lavorato; Luca Fumagalli
Preoperative interleukin-2 subcutaneous immunotherapy may prolong the survival time in advanced colorectal cancer patients.
Oncology 1996;53(4):263-8.
1996: Paolo Lissoni; Fernando Brivio; S Pittalis; Franco Rovelli; R Rescaldani; Maristella Perego; M G Grassi; S Barni; Gabriele Tancini; F Majorca; Luca Fumagalli
Clinical significance of erythrosedimentation rate in cancer in relation to cytokine production: correlation with high IL-6 and low IL-2 blood concentrations.
Journal of biological regulators and homeostatic agents 1996;10(2-3):60-2.
1996: Paolo Lissoni; S Pittalis; Franco Rovelli; S Zecchini; M Casati; M Tremolada; F Pelizzoni
Immunomodulatory properties of a pineal indole hormone other than melatonin, the 5-methoxytryptophol.
Journal of biological regulators and homeostatic agents 1996;10(1):27-30.
1996: Paolo Lissoni; S Pittalis; maria grazia roselli; Franco Rovelli; M G Viganò
Comparison between interleukin-2 and interleukin-12: effects on monocyte functions and their possible importance in the clinical significance of neopterin.
The International journal of biological markers 1996;11(1):58-9.
1996: Paolo Lissoni; Antonio Ardizzoia; S Barni; S Pittalis; F Rossini; A Porta; Gabriele Tancini
Characterization of cancer-related disseminated intravascular coagulation in relation to tumor necrosis factor-alpha blood concentrations: possible therapeutic role of pentoxifylline.
Tumori 1996;82(1):78-80.
1996: S Barni; Paolo Lissoni; Gabriele Tancini; Antonio Ardizzoia; M Cazzaniga
Effects of one-year adjuvant treatment with tamoxifen on bone mineral density in postmenopausal breast cancer women.
Tumori 1996;82(1):65-7.
1996: Paolo Lissoni; S Meregalli; L Nosetto; S Barni; Gabriele Tancini; V Fossati; G Maestroni
Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone.
Oncology 1996;53(1):43-6.
1995: Paolo Lissoni; S Barni; M Cazzaniga; Antonio Ardizzoia; Franco Rovelli; Gabriele Tancini; Fernando Brivio; F Frigerio
Prediction of recurrence in operable breast cancer by postoperative changes in prolactin secretion.
Oncology 1995;52(6):439-42.
1995: Paolo Lissoni; L Vigorè; R Rescaldani; Franco Rovelli; Fernando Brivio; Luisa Giani; S Barni; Gabriele Tancini; Antonio Ardizzoia; M G Viganò
Neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin in AIDS patients with CD4 cell number below 200/mm3: a biological phase-II study.
Journal of biological regulators and homeostatic agents 1995;9(4):155-8.
1995: Paolo Lissoni; Franco Rovelli; E Tisi; Fernando Brivio; Antonio Ardizzoia; S Barni; Gabriele Tancini; M Saudelli; E Cesana; M G Viganò
Relation between macrophage and T helper-2 lymphocyte functions in human neoplasms: neopterin, interleukin-10 and interleukin-6 blood levels in early or advanced solid tumors.
Journal of biological regulators and homeostatic agents 1995;9(4):146-9.
1995: Ryszard Braczkowski; Barbara Zubelewicz; Wojciech Romanowski; Paolo Lissoni; S Barni
Modulation of tumor necrosis factor-alpha (TNF-alpha) toxicity by the pineal hormone melatonin (MLT) in metastatic solid tumor patients.
Annals of the New York Academy of Sciences 1995;768():334-6.
1995: Paolo Lissoni; S Barni; Fernando Brivio; F Rossini; Luca Fumagalli; Antonio Ardizzoia; Gabriele Tancini
A biological study on the efficacy of low-dose subcutaneous interleukin-2 plus melatonin in the treatment of cancer-related thrombocytopenia.
Oncology 1995;52(5):360-2.
1995: Barbara Zubelewicz; Ryszard Braczkowski; Franco Rovelli; Paolo Lissoni; S Pittalis
Stimulation of soluble interleukin-2 release by tumor necrosis factor-alpha in cancer patients.
The International journal of biological markers 1995;10(3):186-7.
1995: Paolo Lissoni; S Barni; Antonio Ardizzoia; F Frigerio; F Paolorossi; M Cazzaniga; Gabriele Tancini; Francesco Rocco; M Aapro
Clinical efficacy of cancer subcutaneous immunotherapy with interleukin-2 in relation to the pretreatment levels of tumor growth factor insulin-like growth factor-1.
Tumori 1995;81(4):261-4.
1995: S Barni; Paolo Lissoni; M Cazzaniga; Antonio Ardizzoia; S Meregalli; V Fossati; Luca Fumagalli; Fernando Brivio; Gabriele Tancini
A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates.
Oncology 1995;52(3):243-5.
1995: Paolo Lissoni; S Barni; V Fossati; Antonio Ardizzoia; M Cazzaniga; Gabriele Tancini; F Frigerio
A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1995;3(3):194-7.
1995: Paolo Lissoni; S Pittalis; Franco Rovelli; L Vigorè; maria grazia roselli; Fernando Brivio
Interleukin-2, melatonin and interleukin-12 as a possible neuroimmune combination in the biotherapy of cancer.
Journal of biological regulators and homeostatic agents 1995;9(2):63-6.
1995: Paolo Lissoni; S Barni; Fernando Brivio; F Rossini; L Fumagalli; G Tancini
Treatment of cancer-related thrombocytopenia by low-dose subcutaneous interleukin-2 plus the pineal hormone melatonin: a biological phase II study.
Journal of biological regulators and homeostatic agents 1995;9(2):52-4.
1995: Paolo Lissoni; Epifanio Scardino; Paolo Favini; S Barni; Gabriele Tancini; A Baccalin; F Verweij; G Strada; R Musci; Francesco Rocco
[Prognostic predictive factors of the clinical response to immunotherapy with subcutaneous interleukin-2, in patients with metastatic renal carcinoma: analysis of 60 cases].
Archivio italiano di urologia, andrologia : organo ufficiale [di] Società italiana di ecografia urologica e nefrologica / Associazione ricerche in urologia 1995;67(2):149-53.
1995: M G Viganò; Paolo Lissoni; S Barni; Gabriele Tancini; Epifanio Scardino; Paolo Favini; A Baccalini; F Verweij; G Strada; Francesco Rocco
[Lymphocyte levels before treatment with subcutaneous interleukin-2 and during maintenance treatment in relation to the clinical efficacy in metastatic renal carcinoma].
Archivio italiano di urologia, andrologia : organo ufficiale [di] Società italiana di ecografia urologica e nefrologica / Associazione ricerche in urologia 1995;67(2):143-7.
1995: Paolo Lissoni; S Barni; S Meregalli; V Fossati; M Cazzaniga; D Esposti; Gabriele Tancini
Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone.
British journal of cancer 1995;71(4):854-6.
1995: Paolo Lissoni; S Barni; Gabriele Tancini; E Mainini; F Piglia; G J Maestroni; A Lewinski
Immunoendocrine therapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumors.
Oncology 1995;52(2):163-6.
1995: Paolo Lissoni; Fernando Brivio; O Brivio; Luca Fumagalli; F Gramazio; M Rossi; G Emanuelli; G Alderi; F Lavorato
Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients.
Journal of biological regulators and homeostatic agents 1995;9(1):31-3.
1995: Paolo Lissoni; S Barni; Antonio Ardizzoia; Epifanio Scardino; Gabriele Tancini; M G Viganò
Correlation between pretreatment serum levels of neopterin and response to interleukin-2 immunotherapy in cancer patients.
Journal of biological regulators and homeostatic agents 1995;9(1):21-3.
1995: F Paolorossi; S Villa; S Barni; Gabriele Tancini; M Andres; Paolo Lissoni
Second-line therapy with interferon-alpha plus vinblastine in metastatic renal cell cancer patients progressed under interleukin-2 subcutaneous immunotherapy.
Tumori 1995;81(1):45-7.
1995: Paolo Lissoni; S Barni; Gabriele Tancini; Antonio Ardizzoia; E Tisi; M Angeli; A Rizzi
Intracavitary therapy of neoplastic effusions with cytokines: comparison among interferon alpha, beta and interleukin-2.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1995;3(1):78-80.
1994: Paolo Lissoni; S Meregalli; V Fossati; F Paolorossi; S Barni; Gabriele Tancini; F Frigerio
A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer.
Tumori 1994;80(6):464-7.
1994: Paolo Lissoni; S Barni; Gabriele Tancini; V Fossati; F Frigerio
Pineal-opioid system interactions in the control of immunoinflammatory responses.
Annals of the New York Academy of Sciences 1994;741():191-6.
1994: Paolo Lissoni; S Barni; Gabriele Tancini; Fernando Brivio; E Tisi; Barbara Zubelewicz; Ryszard Braczkowski
Role of the pineal gland in the control of macrophage functions and its possible implication in cancer: a study of interactions between tumor necrosis factor-alpha and the pineal hormone melatonin.
Journal of biological regulators and homeostatic agents 1994;8(4):126-9.
1994: Paolo Lissoni; S Barni; M Andres; Epifanio Scardino; L Vigoré; R Vezzo; R Rescaldani; Gabriele Tancini
Lymphocytosis decline is not responsible for tumor progression in cancer patients chronically treated with interleukin-2.
Tumori 1994;80(4):283-5.
1994: Paolo Lissoni; S Barni; M Cazzaniga; Antonio Ardizzoia; Franco Rovelli; Fernando Brivio; Gabriele Tancini
Efficacy of the concomitant administration of the pineal hormone melatonin in cancer immunotherapy with low-dose IL-2 in patients with advanced solid tumors who had progressed on IL-2 alone.
Oncology 1994;51(4):344-7.
1994: R Brackowski; Barbara Zubelewicz; Wojciech Romanowski; Paolo Lissoni; S Barni; Gabriele Tancini; G J Maestroni
Preliminary study on modulation of the biological effects of tumor necrosis factor-alpha in advanced cancer patients by the pineal hormone melatonin.
Journal of biological regulators and homeostatic agents 1994;8(3):77-80.
1994: S Barni; Paolo Lissoni; Fernando Brivio; Luca Fumagalli; D Merlini; M Cataldo; Franco Rovelli; Gabriele Tancini
Serum levels of insulin-like growth factor-I in operable breast cancer in relation to the main prognostic variables and their perioperative changes in relation to those of prolactin.
Tumori 1994;80(3):212-5.
1994: Paolo Lissoni; M Cazzaniga; Franco Rovelli; E Mainini; Gabriele Tancini; S Barni
Ondansetron does not stimulate prolactin release in breast cancer patients.
Tumori 1994;80(3):209-11.
1994: Paolo Lissoni; A Bastone; S Barni; Gabriele Tancini; M A Galli
Normalization of idiopathic arterial hypertension following cancer immunotherapy with interleukin-2.
Journal of biological regulators and homeostatic agents 1994;8(2):65-6.
1994: Paolo Lissoni; S Barni; Antonio Ardizzoia; V Fossati; F Paolorossi; Gabriele Tancini
Weekly epirubicin plus low-dose interleukin-2 subcutaneous therapy in breast cancer: preliminary immunobiological results.
Journal of biological regulators and homeostatic agents 1994;8(2):53-5.
1994: Paolo Lissoni; S Barni; Antonio Ardizzoia; G Tancini; A Conti; G Maestroni
A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms.
Cancer 1994;73(3):699-701.
1994: Paolo Lissoni; S Barni; Gabriele Tancini; Antonio Ardizzoia; G Ricci; R Aldeghi; Fernando Brivio; E Tisi; Franco Rovelli; R Rescaldani
A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
British journal of cancer 1994;69(1):196-9.
1994: Paolo Lissoni; S Barni; Antonio Ardizzoia; S Crispino; F Paolorossi; M Andres; Epifanio Scardino; Gabriele Tancini
Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal cell carcinoma.
Oncology 1994;51(1):59-62.
1994: R Aldeghi; Paolo Lissoni; S Barni; Antonio Ardizzoia; Gabriele Tancini; A Piperno; M Pozzi; G Ricci; A Conti; G J Maestroni
Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma.
European journal of cancer (Oxford, England : 1990) 1994;30A(2):167-70.
1994: Paolo Lissoni; Fernando Brivio; Luca Fumagalli; C Galimberti; M Cataldo; M T Marsili; O Brivio; S Barni; Gabriele Tancini; A Angelini
A study of interactions among markers of macrophage functions in metastatic solid tumors: neopterin levels in relation to those of tumor necrosis factor-alpha and of soluble interleukin-2 receptors.
Journal of biological regulators and homeostatic agents 1994;8(1):32-5.
1993: Paolo Lissoni; Fernando Brivio; Antonio Ardizzoia; Gabriele Tancini; S Barni
Subcutaneous therapy with low-dose interleukin-2 plus the neurohormone melatonin in metastatic gastric cancer patients with low performance status.
Tumori 1993;79(6):401-4.
1993: Paolo Lissoni; S Barni; Antonio Ardizzoia; M Andres; Epifanio Scardino; P Cardellini; R Della Bitta; Gabriele Tancini
A randomized study of low-dose interleukin-2 subcutaneous immunotherapy versus interleukin-2 plus interferon-alpha as first line therapy for metastatic renal cell carcinoma.
Tumori 1993;79(6):397-400.
1993: Paolo Lissoni; S Barni; Gabriele Tancini; Franco Rovelli; Antonio Ardizzoia; A Conti; G J Maestroni
A study of the mechanisms involved in the immunostimulatory action of the pineal hormone in cancer patients.
Oncology 1993;50(6):399-402.
1993: Antonio Ardizzoia; Paolo Lissoni; Gabriele Tancini; F Paolorossi; S Crispino; S Villa; S Barni
Respiratory distress syndrome in patients with advanced cancer treated with pentoxifylline: a randomized study.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1993;1(6):331-3.
1993: S Barni; Paolo Lissoni; A Ardizzola; L Vigoré; R Vezzo; R Rescaldani; Gabriele Tancini
Immunotherapy with low-dose subcutaneous interleukin-2 plus beta-interferon as a second-line therapy for metastatic colorectal carcinoma.
Tumori 1993;79(5):343-6.
1993: Paolo Lissoni; S Barni; Antonio Ardizzoia; G Olivini; Fernando Brivio; E Tisi; Gabriele Tancini; D Characiejus; L Kothari
Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatonin.
Journal of biological regulators and homeostatic agents 1993;7(4):121-5.
1993: Paolo Lissoni; S Barni; Gabriele Tancini; Fernando Brivio; P Cardellini; M Vaghi; V Fossati; F Frigerio
Immunoendocrine therapy with interleukin-2 (IL-2) and medroxyprogesterone acetate (MPA): a randomized study with or without MPA in metastatic renal cancer patients during IL-2 maintenance treatment after response or stable disease to IL-2 subcutaneous therapy.
Tumori 1993;79(4):246-9.
1993: S Crispino; Paolo Lissoni; Antonio Ardizzoia; Franco Rovelli; Maristella Perego; M G Grassi; S Barni; S Pittalis; Gabriele Tancini
Effects of granulocyte-macrophage colony stimulating factor on soluble interleukin-2 receptor serum levels and their relation to neopterin and tumor necrosis factor-alpha in cancer patients.
Journal of biological regulators and homeostatic agents 1993;7(3):92-4.
1993: Paolo Lissoni; M A Galli; Gabriele Tancini; S Barni
Prevention by L-carnitine of interleukin-2 related cardiac toxicity during cancer immunotherapy.
Tumori 1993;79(3):202-4.
1993: Paolo Lissoni; S Meregalli; V Fossati; S Barni; Gabriele Tancini; P Barigozzi; F Frigerio
Radioendocrine therapy of brain tumors with the long acting opioid antagonist naltrexone in association with radiotherapy.
Tumori 1993;79(3):198-201.
1993: Paolo Lissoni; S Barni; Gabriele Tancini; Antonio Ardizzoia; Franco Rovelli; M Cazzaniga; Fernando Brivio; A Piperno; R Aldeghi; D Fossati
Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract.
British journal of cancer 1993;67(6):1404-7.
1993: Fernando Brivio; Paolo Lissoni; R Redaelli; A Maggioni; Franco Rovelli; R Rescaldani; F Borin; L Erba; G Alderi
Influence of blood transfusions on surgery-induced immune changes in colorectal carcinoma.
Minerva chirurgica 1993;48(7):331-5.
1993: Paolo Lissoni; S Barni; Gabriele Tancini; M Andres; Epifanio Scardino; P Cardellini; M Frascaroli; Antonio Ardizzoia; S Crispino; D Vicini
[Immunotherapy with low-dose subcutaneous interleukin-2 in metastatic renal carcinoma].
Archivio italiano di urologia, andrologia : organo ufficiale [di] Società italiana di ecografia urologica e nefrologica / Associazione ricerche in urologia 1993;65(2):123-8.
1993: Paolo Lissoni; Antonio Ardizzoia; Maristella Perego; M G Grassi; M Arosio; P D'Amico; M Cazzaniga; S Crispino; Gabriele Tancini; S Barni
Inhibition of tumor necrosis factor-alpha secretion by pentoxifylline in advanced cancer patients with abnormally high blood levels of tumor necrosis factor-alpha.
Journal of biological regulators and homeostatic agents 1993;7(2):73-5.
1993: Paolo Lissoni; S Pittalis; Fernando Brivio; E Tisi; Franco Rovelli; Antonio Ardizzoia; S Barni; Gabriele Tancini; G Giudici; A Biondi
In vitro modulatory effects of interleukin-3 on macrophage activation induced by interleukin-2.
Cancer 1993;71(6):2076-81.
1993: S Barni; C Archili; Paolo Lissoni; F Paolorossi; S Crispino; Gabriele Tancini
A weekly schedule of epirubicin in pretreated advanced breast cancer.
Tumori 1993;79(1):45-8.
1993: Paolo Lissoni; S Barni; Franco Rovelli; Fernando Brivio; Antonio Ardizzoia; Gabriele Tancini; A Conti; G J Maestroni
Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results.
European journal of cancer (Oxford, England : 1990) 1993;29A(2):185-9.
1993: Paolo Lissoni; S Barni; E Tisi; Franco Rovelli; S Pittalis; R Rescaldani; L Vigoré; A Biondi; Antonio Ardizzoia; Gabriele Tancini
In vivo biological results of the association between interleukin-2 and interleukin-3 in the immunotherapy of cancer.
European journal of cancer (Oxford, England : 1990) 1993;29A(8):1127-32.
1993: Paolo Lissoni; Antonio Ardizzoia; E Tisi; F Rossini; S Barni; Gabriele Tancini; A Conti; G J Maestroni
Amplification of eosinophilia by melatonin during the immunotherapy of cancer with interleukin-2.
Journal of biological regulators and homeostatic agents 1993;7(1):34-6.
1993: Paolo Lissoni; M Cazzaniga; Antonio Ardizzoia; F Rossini; G Fiorelli; Gabriele Tancini; S Pittalis; S Barni
Cytokine regulation of iron metabolism: effect of low-dose interleukin-2 subcutaneous therapy on ferritin, transferrin and iron blood concentrations in cancer patients.
Journal of biological regulators and homeostatic agents 1993;7(1):31-3.
1993: Fernando Brivio; Paolo Lissoni; S Barni; Gabriele Tancini; A Ardizzoia; L Erba; G Alderi; V Nociti
Effects of a preoperative course of interleukin-2 on surgical and immunobiological variables in patients with colorectal cancer: a phase 2 study.
The European journal of surgery = Acta chirurgica 1993;159(1):43-7.
1992: S Barni; Paolo Lissoni; M Cazzaniga; Antonio Ardizzoia; F Paolorossi; Fernando Brivio; M Perego; Gabriele Tancini; A Conti; G Maestroni
Neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin as a second-line treatment in metastatic colorectal carcinoma.
Tumori 1992;78(6):383-7.
1992: Paolo Lissoni; Franco Rovelli; S Barni; Antonio Ardizzoia; S Pittalis; E Tisi; V Perlangeli; Gabriele Tancini
Modulation of macrophage response to interleukin-2 immunotherapy by interleukin-3 in cancer patients.
Biological chemistry Hoppe-Seyler 1992;373(12):1217-22.
1992: Paolo Lissoni; E Mainini; Franco Rovelli; C Mazzi; Antonio Ardizzoia; Marco Gelosa; M Capra; M R Rivolta
A clinical study of the pineal hormone melatonin in patients with growth hormone or prolactin secreting pituitary tumours.
The European journal of medicine 1992;1(7):407-10.
1992: Paolo Lissoni; Antonio Ardizzoia; Franco Rovelli; M Perego; P Cardellini; Gabriele Tancini; S Barni
Effect of interferon-alpha on soluble interleukin-2 receptor and tumor necrosis factor increase during immunotherapy with interleukin-2.
The International journal of biological markers 1992;7(4):268-9.
1992: Paolo Lissoni; Franco Rovelli; Gabriele Tancini; E Tisi; M R Rivolta; Antonio Ardizzoia; Fernando Brivio
Inhibitory effect of interleukin-3 on interleukin-2-induced cortisol release in the immunotherapy of cancer.
Journal of biological regulators and homeostatic agents 1992;6(4):113-5.
1992: Paolo Lissoni; Franco Rovelli; E Tisi; D Ballabio; C Benenti; Antonio Ardizzoia; S Barni; B Tancini
Effects of interleukin-2 immunotherapy on soluble lymphocyte markers in cancer patients.
The International journal of biological markers 1992;7(4):260-2.
1992: Paolo Lissoni; Franco Rovelli; E Tisi; Antonio Ardizzoia; V Perlangeli; S Barni; Gabriele Tancini
Endocrine effects of human recombinant interleukin-3 in cancer patients.
The International journal of biological markers 1992;7(4):230-3.
1992: S Crispino; Paolo Lissoni; Antonio Ardizzoia; S Barni; Franco Rovelli; Gabriele Tancini
Effects of granulocyte-macrophage colony stimulating factor on cortisol, growth hormone, prolactin and melatonin in cancer patients (short communication).
Journal of biological regulators and homeostatic agents 1992;6(4):142-4.
1992: Paolo Lissoni; S Barni; Antonio Ardizzoia; Fernando Brivio; Gabriele Tancini; A Conti; G J Maestroni
Immunological effects of a single evening subcutaneous injection of low-dose interleukin-2 in association with the pineal hormone melatonin in advanced cancer patients.
Journal of biological regulators and homeostatic agents 1992;6(4):132-6.
1992: Paolo Lissoni; F Pelizzoni; O Mauri; M Perego; S Pittalis; S Barni
Enhanced secretion of tumour necrosis factor in patients with myocardial infarction.
The European journal of medicine 1992;1(5):277-80.
1992: Antonio Ardizzoia; Paolo Lissoni; Fernando Brivio; E Tisi; Maristella Perego; M G Grassi; S Pittalis; S Crispino; S Barni; Gabriele Tancini
Tumor necrosis factor in solid tumors: increased blood levels in the metastatic disease.
Journal of biological regulators and homeostatic agents 1992;6(3):103-7.
1992: Paolo Lissoni; E Tisi; S Barni; Antonio Ardizzoia; Franco Rovelli; R Rescaldani; D Ballabio; C Benenti; M Angeli; Gabriele Tancini
Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer.
British journal of cancer 1992;66(1):155-8.
1992: E Tisi; Paolo Lissoni; M Angeli; C Arrigoni; E Corno; E Cassina; D Ballabio; C Benenti; S Barni; Gabriele Tancini
Postoperative increase in soluble interleukin-2 receptor serum levels as predictor for early recurrence in non-small cell lung carcinoma.
Cancer 1992;69(10):2458-62.
1992: Paolo Lissoni; S Barni; Antonio Ardizzoia; F Paolorossi; E Tisi; S Crispino; Gabriele Tancini
Intracavitary administration of interleukin-2 as palliative therapy for neoplastic effusions.
Tumori 1992;78(2):118-20.
1992: E Tisi; E Cassina; D Ballabio; C Benenti; M Perego; S Barni; Gabriele Tancini; Paolo Lissoni
Blood levels of atrial natriuretic peptide in non-small cell lung cancer and their changes with surgery.
The International journal of biological markers 1992;7(2):121-2.
1992: Paolo Lissoni; S Barni; Antonio Ardizzoia; S Crispino; F Paolorossi; C Archili; M Vaghi; Gabriele Tancini
Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha.
European journal of cancer (Oxford, England : 1990) 1992;28(1):92-6.
1992: Fernando Brivio; Paolo Lissoni; E Tisi; L Erba; S Barni; Gabriele Tancini; R Rescaldani; G Alderi; V Nociti
Effects of a preoperative therapy with interleukin-2 on surgery-induced lymphocytopenia in cancer patients.
Oncology 1992;49(3):215-8.
1992: Paolo Lissoni; S Barni; Antonio Ardizzoia; F Paolorossi; S Crispino; Gabriele Tancini; E Tisi; C Archili; D De Toma; G Pipino
Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin.
Oncology 1992;49(5):336-9.
1991: Paolo Lissoni; Fernando Brivio; S Pittalis; Maristella Perego; Antonio Ardizzoia; O Mauri; S Barni; S Crispino; Gabriele Tancini
Decrease in cholesterol levels during the immunotherapy of cancer with interleukin-2.
British journal of cancer 1991;64(5):956-8.
1991: Paolo Lissoni; S Barni; O Mauri; F Pelizzoni; S Pittalis; G Osculati; Franco Valagussa
[Cardioangioimmunology: the immune implications in the principle cardiovascular pathologies].
Giornale italiano di cardiologia 1991;21(10):1139-46.
1991: S Barni; Paolo Lissoni; F Paolorossi; R Rescaldani; S Crispino; C Archili; G Cattaneo; Gabriele Tancini
Mitoxantrone as a single agent in pretreated metastatic breast cancer: effects on T lymphocyte subsets and their relation to clinical response.
Tumori 1991;77(3):227-31.
1991: Paolo Lissoni; S Barni; Franco Rovelli; S Crispino; Gabriele Fumagalli; S Pescia; M Vaghi; G Camesasca; Gabriele Tancini
Neuroendocrine effects of subcutaneous interleukin-2 injection in cancer patients.
Tumori 1991;77(3):212-5.
1991: S Barni; Paolo Lissoni; D Mandelli; C Archili; G Real; A L Sormani; R Caprotti; Gabriele Tancini
Relation between surgery-induced prolactin increase and the menstrual cycle phase at time of surgery in premenopausal breast cancer.
The International journal of biological markers 1991;6(2):103-6.
1991: Fernando Brivio; Paolo Lissoni; D Mancini; E Tisi; Gabriele Tancini; S Barni; V Nociti
Effect of antitumor surgery on soluble interleukin-2 receptor serum levels.
American journal of surgery 1991;161(4):466-9.
1991: E Tisi; Paolo Lissoni; Franco Rovelli; D Mandelli; S Barni; Gabriele Tancini
Blood levels of IGF-I in non-small cell lung cancer: relation to clinical data.
The International journal of biological markers 1991;6(2):99-102.
1991: Paolo Lissoni; S Barni; Franco Rovelli; Gabriele Tancini
Lower survival in metastatic cancer patients with reduced interleukin-2 blood concentrations. Preliminary report.
Oncology 1991;48(2):125-7.
1991: Paolo Lissoni; E Tisi; Fernando Brivio; S Barni; Franco Rovelli; M Perego; Gabriele Tancini
Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2.
European journal of cancer (Oxford, England : 1990) 1991;27(8):1014-6.
1991: Paolo Lissoni; S Barni; G Cattaneo; Gabriele Tancini; G Esposti; D Esposti; Franco Fraschini
Clinical results with the pineal hormone melatonin in advanced cancer resistant to standard antitumor therapies.
Oncology 1991;48(6):448-50.
1990: Paolo Lissoni; S Barni; G Cattaneo; C Archili; M Perego; Gabriele Tancini
Evaluation of the cardiovascular toxicity related to cancer immunotherapy with interleukin-2 by monitoring atrial natriuretic peptide secretion: a case report.
Tumori 1990;76(6):603-5.
1990: Paolo Lissoni; Fernando Brivio; S Barni; Gabriele Tancini; G Cattaneo; C Archili; A Conti; G J Maestroni
Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: its efficacy in preventing hypotension.
Anticancer research 1990;10(6):1759-61.
1990: Antonio Colombo; S Crispino; Gabriele Tancini; A Personeni; R Taino; E Sarti; S Barni; Paolo Lissoni; F Placa; P Mazzola
[Radiotherapy plus a combination of cisplatin and 5-fluorouracil for locally advanced head and neck neoplasms. Study of feasibility and preliminary results].
La Radiologia medica 1990;80(5):713-8.
1990: Paolo Lissoni; Gabriele Tancini; Franco Rovelli; G Cattaneo; C Archili; S Barni
Serum interleukin-2 levels in relation to the neuroendocrine status in cancer patients.
British journal of cancer 1990;62(5):838-9.
1990: Paolo Lissoni; F Pelizzoni; Graziano Grugni; Gabriele Guzzaloni; O Mauri; C Archili; M A Galli; F Morabito
Melatonin response to atrial natriuretic peptide administration in healthy volunteers.
Journal of cardiovascular pharmacology 1990;16(5):850-2.
1990: Paolo Lissoni; S Barni; G Cattaneo; C Archili; S Crispino; Gabriele Tancini; L D'Angelo; S Magni; G Fiorelli
Activation of the complement system during immunotherapy of cancer with interleukin-2: a possible explanation of the capillary leak syndrome.
The International journal of biological markers 1990;5(4):195-7.
1990: Paolo Lissoni; M A Galli; S Barni; V Colombo; F Pelizzoni; R Fumagalli; Gabriele Tancini
[The cardiovascular toxicity of interleukin-2: the pathogenic mechanisms and treatment].
Giornale italiano di cardiologia 1990;20(7):631-5.
1990: Paolo Lissoni; S Barni; C Archili; G Cattaneo; Franco Rovelli; A Conti; G J Maestroni; Gabriele Tancini
Endocrine effects of a 24-hour intravenous infusion of interleukin-2 in the immunotherapy of cancer.
Anticancer research 1990;10(3):753-7.
1990: S Barni; Paolo Lissoni; F Paolorossi; S Crispino; C Archili; Gabriele Tancini
A study of the pineal hormone melatonin as a second line therapy in metastatic colorectal cancer resistant to fluorouracil plus folates.
Tumori 1990;76(1):58-60.
1990: Paolo Lissoni; S Barni; Franco Rovelli; R Rescaldani; V Rizzo; A Biondi; Gabriele Tancini
Correlation of serum interleukin-2 levels, soluble interleukin-2 receptors and T lymphocyte subsets in cancer patients.
Tumori 1990;76(1):14-7.
1990: Paolo Lissoni; E Mainini; C Mazzi; G Cattaneo; S Barni
A study of pineal-prolactin interaction: prolactin response to an acute melatonin injection in patients with hyperprolactinemia.
Journal of endocrinological investigation 1990;13(2):85-9.
1990: Simonetta Viviani; E Negretti; A Orazi; Gabriella Sozzi; Armando Santoro; Paolo Lissoni; G Esposti; Franco Fraschini
Preliminary studies on melatonin in the treatment of myelodysplastic syndromes following cancer chemotherapy.
Journal of pineal research 1990;8(4):347-54.
1990: Paolo Lissoni; S Crispino; S Barni; A Sormani; Fernando Brivio; F Pelizzoni; A Brenna; G Bratina; Gabriele Tancini
Pineal gland and tumor cell kinetics: serum levels of melatonin in relation to Ki-67 labeling rate in breast cancer.
Oncology 1990;47(3):275-7.
1990: C Archili; Paolo Lissoni; G Cattaneo; Franco Rovelli; Fernando Brivio; Gabriele Tancini; S Barni
Lack of changes in soluble interleukin-2 receptor serum levels during chemotherapy-induced lymphocyte damage.
The International journal of biological markers 1990;5(1):43-5.
1990: Paolo Lissoni; F Pelizzoni; M Perego; G Fondrini; Graziano Grugni; Gabriele Guzzaloni; F Morabito
A study of heart-pineal interactions: atrial natriuretic peptide response to melatonin administration in healthy humans.
Journal of pineal research 1990;9(3):167-70.
1990: Paolo Lissoni; A L Sormani; Gabriele Tancini; G Cattaneo; C Archili; D Mandelli; S Crispino; F Paolorossi; S Barni
Postoperative hyperprolactinaemia and early recurrence rate in breast cancer.
European journal of cancer (Oxford, England : 1990) 1990;26(9):953-6.
1990: Gabriele Tancini; S Barni; R Rescaldani; G Fiorelli; S Vivani; Paolo Lissoni
Analysis of T helper and suppressor lymphocyte subsets in relation to the clinical stage of solid neoplasms.
Oncology 1990;47(5):381-4.
1990: Paolo Lissoni; Gabriele Tancini; C Archili; R Rescaldani; G Cattaneo; S Crispino; S Barni
Changes in T lymphocyte subsets after single dose epirubicin.
European journal of cancer (Oxford, England : 1990) 1990;26(6):767-8.
1990: Paolo Lissoni; S Barni; Franco Rovelli; Simonetta Viviani; G J Maestroni; A Conti; Gabriele Tancini
The biological significance of soluble interleukin-2 receptors in solid tumors.
European journal of cancer (Oxford, England : 1990) 1990;26(1):33-6.
1989: S Crispino; A Brenna; D Colombo; B Flores; S D'Amico; Paolo Lissoni; S Barni; F Paolorossi; G Bratina; Gabriele Tancini
Ki-67 labeling index in breast cancer.
Tumori 1989;75(6):557-62.
1989: S Crispino; Gabriele Tancini; S Barni; Paolo Lissoni
Evidence for altered hypothalamic-hypophyseal-gonadal axis in untreated patients with testicular germ-cell tumor.
Tumori 1989;75(5):505-9.
1989: Paolo Lissoni; S Barni; R Rescaldani; Franco Rovelli; Gabriele Tancini
Serum levels of soluble interleukin-2 receptors and their relation to lymphocyte subpopulations in patients with metastatic solid tumours.
British journal of cancer 1989;60(4):616-7.
1989: Paolo Lissoni; Simonetta Viviani; A Santoro; S Barni; Gabriele Tancini
Serum levels of interleukin-2 in cancer patients: preliminary considerations.
The International journal of biological markers 1989;4(4):203-6.
1989: Paolo Lissoni; Gabriele Tancini; S Barni; Simonetta Viviani; C Archili; G Cattaneo; G Fiorelli
Alterations of pineal gland and of T lymphocyte subsets in metastatic cancer patients: preliminary results.
Journal of biological regulators and homeostatic agents 1989;3(4):181-3.
1989: Paolo Lissoni; V Rizzo; S Barni; R Rescaldani; Franco Rovelli; A Biondi; C Archili; F Frigerio; Gabriele Tancini
Interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors in patients with solid tumors are not correlated.
The International journal of biological markers 1989;4(3):170-3.
1989: S Barni; Paolo Lissoni; A Sormani; F Pelizzoni; Fernando Brivio; S Crispino; Gabriele Tancini
The pineal gland and breast cancer: serum levels of melatonin in patients with mammary tumors and their relation to clinical characteristics.
The International journal of biological markers 1989;4(3):157-62.
1989: Paolo Lissoni; S Barni; Gabriele Tancini; Simonetta Viviani; Franco Rovelli; R Rescaldani; G Fiorelli
Effects of cancer chemotherapy on the relation between serum levels of soluble interleukin-2 receptors and CD4/CD8 ratio in patients with solid neoplasms.
Journal of biological regulators and homeostatic agents 1989;3(3):131-3.
1989: M Tagliabue; Paolo Lissoni; S Barni; I Macchi; Gabriele Tancini; S Crispino; L Ferri; E Salvini
A radiologic study by CT scan of pineal size in cancer patients: correlation to melatonin blood levels.
Tumori 1989;75(3):226-8.
1989: Paolo Lissoni; S Barni; S Crispino; Gabriele Tancini; F Fraschini
Endocrine and immune effects of melatonin therapy in metastatic cancer patients.
European journal of cancer & clinical oncology 1989;25(5):789-95.
1989: Gabriele Tancini; S Barni; S Crispino; F Paolorossi; Paolo Lissoni
A study of thyroid function in cancer cachexia.
Tumori 1989;75(2):185-8.
1989: S Crispino; G Lombardi; G Bratina; Paolo Lissoni; S Barni; Gabriele Tancini
Malignant testicular germ cell tumor in father and son: a case report.
Tumori 1989;75(2):177-80.
1989: Gabriele Tancini; Paolo Lissoni; S Barni; R Rescaldani; Franco Rovelli; A Sormani; S Crispino; T Saporito; E Tisi; C Benenti
Serum levels of soluble interleukin-2 receptors and their relation to CD4/CD8 ratio in patients with advanced solid tumors.
The International journal of biological markers 1989;4(2):123-4.
1989: Paolo Lissoni; S Barni; F Garuti; R Astuti; Gabriele Tancini
Opioid receptors in human neoplasms: growth hormone and prolactin response to morphine, met-enkephalin and buprenorphine in cancer patients.
The International journal of biological markers 1989;4(1):55-6.
1989: Paolo Lissoni; S Crispino; S Barni; Gabriele Tancini
Prolactin secretion in testicular cancer patients.
The International journal of biological markers 1989;4(1):27-30.
1988: Franco Rovelli; Paolo Lissoni; S Crispino; S Barni; G Fumagalli; F Paolorossi; Gabriele Tancini
Increased level of soluble interleukin-2 receptor in advanced solid tumors: a preliminary study.
Tumori 1988;74(6):633-7.
1988: D Esposti; Paolo Lissoni; Gabriele Tancini; S Barni; S Crispino; F Paolorossi; Franco Rovelli; L Ferri; G Cattaneo; G Esposti
A study on the relationship between the pineal gland and the opioid system in patients with cancer. Preliminary considerations.
Cancer 1988;62(3):494-9.
1988: S Barni; Paolo Lissoni; S Crispino; Franco Rovelli; G Esposti; Franco Fraschini; Gabriele Tancini
Serum levels of melatonin in cancer patients and their relation to body sizes.
The International journal of biological markers 1988;3(3):193-6.
1988: Paolo Lissoni; Gabriele Tancini; S Barni; S Crispino; F Paolorossi; Franco Rovelli; G Cattaneo; Franco Fraschini
Melatonin increase as predictor for tumor objective response to chemotherapy in advanced cancer patients.
Tumori 1988;74(3):339-45.
1988: S Barni; Paolo Lissoni; Franco Rovelli; S Crispino; F Paolorossi; D Esposti; G Esposti; Franco Fraschini; Gabriele Tancini
Alteration of opioid peptide circadian rhythm in cancer patients.
Tumori 1988;74(3):357-60.
1988: Paolo Lissoni; S Barni; S Crispino; G Cattaneo; Gabriele Tancini
Endocrine and clinical effects of an LHRH analogue in pretreated advanced breast cancer.
Tumori 1988;74(3):303-8.
1988: S Barni; Paolo Lissoni; S Crispino; G Cattaneo; Franco Rovelli; G Fumagalli; Gabriele Tancini
Neuroimmunomodulation in cancer patients: correlations between melatonin and beta-endorphin blood levels and T helper/suppressor ratio.
The International journal of biological markers 1988;3(2):82-6.
1988: D Esposti; Paolo Lissoni; R Mauri; Franco Rovelli; L Orsenigo; S Pescia; G Vegetti; G Esposti; Franco Fraschini
The pineal gland-opioid system relation: melatonin-naloxone interactions in regulating GH and LH releases in man.
Journal of endocrinological investigation 1988;11(2):103-6.
1988: Paolo Lissoni; S Barni; Gabriele Tancini; S Crispino; F Paolorossi; G Cattaneo; Valeria Lucini; M Mariani; D Esposti; G Esposti
Relation between lymphocyte subpopulations and pineal function in patients with early or metastatic cancer.
Annals of the New York Academy of Sciences 1988;521():290-9.
1988: D Esposti; G Esposti; Paolo Lissoni; L Parravicini; Franco Fraschini
Action of morphine on melatonin release in the rat.
Journal of pineal research 1988;5(1):35-9.
1987: Paolo Lissoni; S Barni; F Paolorossi; S Crispino; Franco Rovelli; L Ferri; G Delitala; Gabriele Tancini
Evidence for altered opioid activity in patients with cancer.
British journal of cancer 1987;56(6):834-7.
1987: Paolo Lissoni; S Barni; Gabriele Tancini; S Crispino; F Paolorossi; Valeria Lucini; M Mariani; G Cattaneo; D Esposti; G Esposti
Clinical study of melatonin in untreatable advanced cancer patients.
Tumori 1987;73(5):475-80.
1987: Antonio Colombo; S Crispino; S Barni; F Paolorossi; F Frigerio; Gabriele Tancini; Paolo Lissoni; F Placa; P Mazzola; S Nava
[Concomitant therapy with cisplatin and radiotherapy in locally advanced tumors of the cervico-facial area].
La Radiologia medica 1987;74(4):334-7.
1987: S Barni; F Frigerio; Paolo Lissoni; S Crispino; F Paolorossi
Anal squamous cell carcinoma arising on radio-dermatitis cured with chemotherapy alone: case report.
Tumori 1987;73(4):423-4.
1987: S Barni; Paolo Lissoni; F Paolorossi; S Crispino; Franco Rovelli; L Ferri; A Sormani; U D'Alonso; A Bugatti; V Nociti
Effects of radical mastectomy on prolactin blood levels in patients with breast cancer.
European journal of cancer & clinical oncology 1987;23(8):1141-5.
1987: Paolo Lissoni; A Bastone; R Sala; R Mauri; Franco Rovelli; Simonetta Viviani; E Bajetta; D Esposti; G Esposti; L di Bella
The clinical significance of melatonin serum determination in oncological patients and its correlations with GH and PRL blood levels.
European journal of cancer & clinical oncology 1987;23(7):949-57.
1987: Paolo Lissoni; F Paolorossi; S Barni; Gabriele Tancini; S Crispino; Franco Rovelli; L Ferri; G Esposti; D Esposti; Franco Fraschini
Correlation between changes in prolactin and melatonin serum levels after radical mastectomy.
Tumori 1987;73(3):263-7.
1987: Paolo Lissoni; S Barni; S Crispino; Gabriele Tancini; F Paolorossi; L Ferri; G Delitala
Synthetic enkephalin analog in the treatment of cancer chemotherapy-induced vomiting.
Cancer treatment reports 1987;71(6):665-6.
1987: S Barni; Paolo Lissoni; Gabriele Tancini; S Crispino; F Paolorossi; Franco Rovelli; G Fumagalli; L Ferri; D Esposti; G Esposti
Acute effects of various chemotherapeutic combinations on hypophyseal and pineal hormone secretions in cancer patients.
Tumori 1987;73(2):181-5.
1986: S Barni; Paolo Lissoni; Gabriele Tancini; S Crispino; F Paolorossi; Franco Rovelli; G Fumagalli; L Ferri
Prolactin response to thyrotropin-releasing hormone in early and advanced human breast cancer.
Tumori 1986;72(4):399-403.
1986: Paolo Lissoni; M Resentini; R Mauri; Franco Fraschini; F Morabito
[Levels of melatonin in prepubertal and pubertal subjects during different seasons of the year].
Minerva pediatrica 1986;38(11-12):471-6.
1986: Paolo Lissoni; Simonetta Viviani; E Bajetta; R Buzzoni; A Barreca; R Mauri; M Resentini; F Morabito; D Esposti; G Esposti
A clinical study of the pineal gland activity in oncologic patients.
Cancer 1986;57(4):837-42.
1986: Paolo Lissoni; D Esposti; G Esposti; R Mauri; M Resentini; F Morabito; P Fumagalli; A Santagostino; G Delitala; Franco Fraschini
A clinical study on the relationship between the pineal gland and the opioid system.
Journal of neural transmission 1986;65(1):63-73.
1985: R Mauri; Paolo Lissoni; M Resentini; C De Medici; F Morabito; S Djemal; L Di Bella; Franco Fraschini
Effects of melatonin on PRL secretion during different photoperiods of the day in prepubertal and pubertal healthy subjects.
Journal of endocrinological investigation 1985;8(4):337-41.
1984: R Mauri; M Resentini; Paolo Lissoni; F Morabito
[Prolactin response to TRH in patients with idiopathic delayed puberty].
Minerva pediatrica 1984;36(20):1013-6.
1982: M Resentini; G Canto; P Lacqua; Paolo Lissoni; R Mauri; G Marincola; F Morabito
[The lipid profile and nephelometry in obesity in children and juveniles].
Minerva pediatrica 1982;34(20):861-70.